Full-Time

AI Business Analyst

Applied & Agentic AI Systems

Updated on 9/13/2026

Deadline 9/27/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Hyderabad, Telangana, India

In Person

Working hours include evening IST hours to overlap with Central European Time.

Category
Business & Strategy (1)
Required Skills
LLM
Microsoft Azure
Python
Graph Databases
SQL
RAG
AWS
JIRA
Observability
Confluence

Get referred to Roche

See people who can refer or advise you

Requirements
  • 8+ years of IT Business Analysis experience supporting enterprise-scale software solutions, system integrations, and business processes.
  • 5+ years of experience in highly regulated environments, preferably in pharmaceutical, biotechnology, medical devices, or clinical healthcare sectors.
  • 3+ years of experience in Agile/Scrum product delivery, including product backlog management, detailed User Story writing, and support for agile ceremonies.
  • Hands-on experience with Generative AI or machine learning projects, including data preparation, prompt development, or AI application testing.
  • Experience delivering computerized system validation or software assurance under industry-standard quality guidelines and electronic records regulations.
  • Experience working with cross-functional, globally distributed engineering squads including developers, architects, quality assurance, and validation teams.
  • Experience leveraging AI productivity tools and coding assistants such as Claude Code, ChatGPT, Codex, or GitHub Copilot in an agentic software development lifecycle.
  • Expert-level proficiency in requirements elicitation, specification, modeling, verification, and traceability.
  • Proficiency in large language model prompt engineering, including designing, evaluating, and refining prompts and constructing system prompts and templates.
  • Advanced ability to analyze complex data structures, assess AI model outputs, trace data lineage, interpret technical specifications, and evaluate system behaviors.
  • Deep knowledge of regulatory and quality protocols, software validation, quality assurance standards, and global guidelines for electronic records and digital signatures.
  • Advanced skills in process mapping, business workflow design, and data flow diagramming.
  • Experience conducting financial analyses, cost-benefit modeling, and total cost of ownership calculations for enterprise platforms.
  • Ability to build consensus across conflicting viewpoints, challenge unrealistic business requests, and translate between business and technical language.
  • Strong understanding of AI applications and traditional software development lifecycle methodologies.
  • English proficiency at C1+ level.
  • Availability to work hours that overlap with Central European Time, typically during the IST evening.
Responsibilities
  • Manage the full AI project lifecycle from opportunity identification through deployment and value realization.
  • Translate business goals into prioritized product backlogs, epics, and user stories with clear acceptance criteria.
  • Define MVP and MMR strategies to iteratively deliver business value while managing project risks.
  • Act as a Proxy Product Owner when necessary, making decisions on prioritization and sprint goals.
  • Design and optimize large language model prompts for accurate, secure, and relevant model outputs.
  • Prototype agentic workflows and evaluate model responses using Python scripting and SQL data exploration.
  • Develop specifications for dynamic Generative UI components and retrieval-augmented generation pipeline context mappings.
  • Lead requirements workshops and JAD sessions to elicit business and functional specifications.
  • Author standard-compliant artifacts including URS, FRS, and as-is/to-be process maps.
  • Conduct gap analyses and re-engineering assessments to optimize and automate manual workflows.
  • Guide compliance-by-design strategies for AI deployments following GAMP 5, 21 CFR Part 11, and Annex 11.
  • Guide risk-based computer software assurance and computerized system validation activities, authoring risk assessments, trace matrices, and validation reports.
  • Enforce data integrity controls and system classifications to preserve validated states.
  • Apply governance guardrails, escalation triggers, and observability requirements to agentic AI systems.
  • Assess AI-specific risks such as drift, leakage, and tool misuse, and formulate total cost of ownership and return on investment business cases.
  • Manage formal change requests and present impact analyses to change advisory and emergency change advisory boards.
  • Maintain system configuration documentation and audit readiness for internal and regulatory inspections.
  • Act as the information technology subject matter expert during audits, presenting validation evidence and requirements engineering practices.
  • Author standard operating procedures, manuals, and training materials to support business readiness and operational transitions.
Desired Qualifications
  • Strong product thinking and backlog management using JIRA and Confluence, with the ability to act as a Proxy Product Owner, define MVPs, prioritize backlogs, and drive sprint goals.
  • Broad understanding of large language model architectures, retrieval-augmented generation and GraphRAG concepts, multi-agent frameworks, and vector and graph databases.
  • Understanding of ITIL-based change management, incident management, and configuration management database architectures.
  • Experience partnering with quality assurance to review test plans, coordinate User Acceptance Testing, and verify test coverage using Requirements Traceability Matrices.
  • Strong interest in applying agentic Software Development Lifecycle practices and tools.
  • IIBA credentials such as Certified Business Analysis Professional or Certification of Capability in Business Analysis, Project Management Institute Professional in Business Analysis, or Scrum Alliance Certified Scrum Product Owner or Product Owner certifications.
  • Basic familiarity with cloud service models such as AWS and Azure and cloud-native application deployments.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
  • FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
  • Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.

What critics are saying

  • Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
  • Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
  • Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.

What makes Roche unique

  • Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
  • Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
  • Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 24th, 2026
Roche and Eli Lilly win FDA clearance for Alzheimer's blood test for over-55s

Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.